#SCAyodhaVerdict #TelecomWar #YesBank

SENSEX
NIFTY 50
Hang Seng
Taiwan Weighted
MCX GOLD DEC 05
MCX SILVER DEC 05
USD/INR
EUR/INR80.0630

SENSEX
NIFTY 50
NIFTY MIDCAP 100
S&P BSE MIDCAP
Hang Seng
Taiwan Weighted
DAX
Nasdaq
MCX GOLD DEC 05
MCX SILVER DEC 05
MCX CRUDEOIL NOV 19
MCX NATURALGAS NOV 25
USD/INR
EUR/INR
GBP/INR
JPY/INR

Market erases gains, Nifty50 turns flat; FMCG stocks falter

Asia shares await on US-China trade progress, Fed events

Oil prices rise after reports of decline in US crude stocks, Fed's comments on economy

Indian rupee opens marginally higher at 72.07 against the US dollar

Earnings

Lupin Q4 results today: Drugmaker expected to swing to profit

Updated : May 15, 2019 08:32 AM IST

The street is expecting revenue growth of 12.5 percent and EBITDA higher by 25.6 percent.

Margins are seen up 19.6 percent versus 17.6 percent year-on-year.

Lupin will report its fourth-quarter earnings on Wednesday and analysts expect the drugmaker to swing to profit this quarter and post a near 13 percent growth in Q4 revenue.

The street is expecting revenue growth of 12.5 percent and EBITDA higher by 25.6 percent. Margins are seen up 19.6 percent versus 17.6 percent year-on-year.

The company is expected to report a profit of Rs 472 crore versus a loss of Rs 783.5 crore reported in the same quarter last year. In 2018, the company had taken an impairment of Gavis, which was around Rs 1,464 crore.

Revenue growth is driven by the US markets specifically on account of Ranexa generics, a chest pain drug that they had launched in February 2019 with exclusivity and the size of the drug is $750 million.

Estimates suggest Lupin can make up to $70 million from this drug. Besides, other drugs like Solosec generic, Lisinopril generic, will also aid US sales. So US sales would see an increase of around $50-90 million quarter-on-quarter. India growth is likely to be 10-12 percent.

Overall the commentary from the management would be key since the company received OAI for its two plants along with the status of Goa reinspection. Investors/analysts would also watch out for the company’s cost-cutting initiatives.

primo org

Have you signed up for Primo, our daily newsletter?

It has all the stories and data on the market, business, economy and tech that you need to know.

To keep watching CNBC-TV18, India's No. 1 English Business News Channel, call your Cable or DTH Operator and subscribe now for just Rs. 4 per month. You can also subscribe to CNBC-TV18 Prime HD for Re 1/- per month.Find out more

You May Also Like

Growth in the number of Indian students in the US falls for third straight year

Growth in the number of Indian students in the US falls for third straight year

Jaypee Infratech resolution: NBCC offers 1,426 acres to banks

Jaypee Infratech resolution: NBCC offers 1,426 acres to banks

Aramco IPO: Saudi Arabia seeks $1.7 trillion in valuation

Aramco IPO: Saudi Arabia seeks $1.7 trillion in valuation

Trending on CNBC-TV18

Live TV

recommended for you